Clinical Thyroidology® for the Public

Summaries for the Public from recent articles in Clinical Thyroidology
Table of Contents | PDF File for Saving and Printing

THYROID CANCER
Fine-tuning cancer risk and response: Practical implications of the 2025 ATA Thyroid Cancer Guidelines

Instagram Youtube LinkedIn Facebook X

 

BACKGROUND
The majority of patients with thyroid cancer do very well. Indeed, almost 40% of thyroid cancers are less than 1 cm and have an excellent prognosis. To further assist clinicians with the rational targeting of treatment and monitoring, the 2025 ATA guidelines introduced an updated cancer risk stratification system that recommends continuing risk assessment after each treatment decision and subsequent action to reassess the risk of cancer recurrence. The appropriate future monitoring and treatment is therefore based on the new risk assessment, rather than the initial risk assessment driven largely by the initial diagnosis and cancer staging data.

The 2025 ATA guidelines make several important adjustments to risk stratification from the 2015 guidelines: (1) they create a visual separation between risk stratification for different types of thyroid cancer (papillary, follicular, and oncocytic), (2) they add multiple cancers within the thyroid and remove molecular profile from recurrence risk approximation, and (3) they introduce an “additive” approach to risk when multiple risk features are identified. However, the clinical practice implications of these new guidelines remain unknown.

The present study aimed to compare cancer classification between the 2015 and the 2025 guidelines for papillary thyroid cancer and whether cancer risk redistribution corresponded with final disease outcome.

THE FULL ARTICLE TITLE
Moneta C, et al. Validation of the 2025 ATA risk stratification system in a cohort of patients with papillary thyroid carcinoma. J Clin Endocrinol Metab 2026;111(10):2883–2889

SUMMARY OF THE STUDY
This was a study of consecutive adult patients diagnosed with papillary thyroid cancer between January 1969 and December 2024. All patients underwent initial surgical treatment followed by radioactive iodine treatment, if indicated. Patients were clinically evaluated at 3- to 12-month intervals with blood cancer markers and neck ultrasound, with additional imaging as needed. Each patient was classified according to both the 2015 and 2025 risk stratification system.

The study group was composed of 670 patients. The average age at diagnosis was 47 years; 90% (602) had undergone total thyroidectomy, 31% (207) had undergone lymph node dissection, and 43% (288) had received radioactive iodine therapy. Cancer characteristics included the following: primary cancer with an average size of 1.2 cm, vascular invasion in 11.3% (76), extrathyroidal extension in 26.3% (176), multiple cancers in 30% (200), presence of spread to the lymph nodes in 18% (121) and spread outside of the neck in 0.7%.

Among these patients, 2015 risk stratification yielded 61% in the low-risk group, 29% in the intermediate-risk group, and 10% in the high-risk group. Using the 2025 risk system, these patients were categorized as 48% low risk, 22% low–intermediate risk, 19% intermediate–high risk, and 12% high risk. Overall, the proportion of patients with low risk classification decreased by 22%, intermediate risk (composed of low–intermediate and intermediate– high risk classes) increased by 42%, and high risk increased by 15%.

There was no difference in persistent cancer among 2015 and 2025 low-risk groups (4.1% vs. 4.9%). The 2025 low–intermediate-risk group had lower persistent cancer compared to 2015 intermediate-risk (12.2% vs. 22.7%), and persistent cancer was similar between the 2015 intermediate-risk and 2025 intermediate–high-risk groups (22.7% vs. 22.1%) as well as between the 2015 and 2025 high-risk groups (47.8% vs. 48).

WHAT ARE THE IMPLICATIONS OF THIS STUDY?
This study shows that the risk stratification system in the 2025 American Thyroid Association guidelines for thyroid cancer defines a clinically meaningful low-intermediate risk category. However, the reclassification of 2015 low-risk patients to 2025 low-intermediate risk does not necessarily indicate benefit from more intensive therapy. The new categorizations also may have an impact on how patients perceive their disease and may add a layer of anxiety to those reclassified to a higher risk category.

— Alan P. Farwell, MD

ABBREVIATIONS & DEFINITIONS

Papillary thyroid cancer: the most common type of differentiated thyroid cancer. There are 4 variants of papillary thyroid cancer: classic, follicular, tall-cell and noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP).

Follicular thyroid cancer: the second most common type of differentiated thyroid cancer.

Oncocytic thyroid cancer: least common type of differentiated thyroid cancer, which has a higher rate of recurrence outside of the neck. Further, oncocytic thyroid cancer is more resistant to radioactive iodine therapy than other forms of differentiated thyroid cancer.

Thyroidectomy: surgery to remove the entire thyroid gland. When the entire thyroid is removed it is termed a total thyroidectomy. When less is removed, such as in removal of a lobe, it is termed a partial thyroidectomy.

Radioactive iodine (RAI): this plays a valuable role in diagnosing and treating thyroid problems since it is taken up only by the thyroid gland. I-131 is the destructive form used to destroy thyroid tissue in the treatment of thyroid cancer and with an overactive thyroid. I-123 is the nondestructive form that does not damage the thyroid and is used in scans to take pictures of the thyroid (Thyroid Scan) or to take pictures of the whole body to look for thyroid cancer (Whole Body Scan).